Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate

In this study, we analyze the effect of ambroxol treatment on GCase activity in healthy nonhuman primates. We show that daily administration of ambroxol results in increased brain GCase activity. Our work further indicates that ambroxol should be investigated as a novel therapy for both PD and neuronopathic GD in humans. Treatment with 100 mg of ambroxol leads to approximately a 20% increase in brain glucocerebrosidase activity in a nonhuman primate.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fsyn.21967

Source: Synapse - March 16, 2017 Category: Neurology Authors: Anna Migdalska ‐Richards, Wai Kin D. Ko, Qin Li, Erwan Bezard, Anthony H. V. Schapira Tags: SHORT COMMUNICATION Source Type: research